THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE

Innovation Pathways, Llc, Palo Alto CA

Investigators

Abstract

This proposal, using partial body irradiation (PBI) animal models to study the delayed effects of acute radiation exposure (DEARE) on survival due to multi-organ injury, including the lungs. The proposal is focused on supporting the critical path for FDA approval of an Innovation Pathways, small molecule TGFβ Receptor-1 kinase inhibitor MCM. Under the guidance criteria of the FDA “Animal Rule” (AR).